Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm

BCR::ABL1-negative myeloproliferative neoplasms (MPNs) include three major subgroups—polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)—which are characterized by aberrant hematopoietic proliferation with an increased risk of leukemic transformation. Besides the...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbou, Norman, Piazzola, Pauline, Gabert, Jean, Ernest, Vincent, Arcani, Robin, Couderc, Anne-Laure, Tichadou, Antoine, Roche, Pauline, Farnault, Laure, Colle, Julien, Ouafik, L’houcine, Morange, Pierre, Costello, Régis, Venton, Geoffroy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818322/
https://www.ncbi.nlm.nih.gov/pubmed/36611899
http://dx.doi.org/10.3390/cells12010105
_version_ 1784864956954443776
author Abbou, Norman
Piazzola, Pauline
Gabert, Jean
Ernest, Vincent
Arcani, Robin
Couderc, Anne-Laure
Tichadou, Antoine
Roche, Pauline
Farnault, Laure
Colle, Julien
Ouafik, L’houcine
Morange, Pierre
Costello, Régis
Venton, Geoffroy
author_facet Abbou, Norman
Piazzola, Pauline
Gabert, Jean
Ernest, Vincent
Arcani, Robin
Couderc, Anne-Laure
Tichadou, Antoine
Roche, Pauline
Farnault, Laure
Colle, Julien
Ouafik, L’houcine
Morange, Pierre
Costello, Régis
Venton, Geoffroy
author_sort Abbou, Norman
collection PubMed
description BCR::ABL1-negative myeloproliferative neoplasms (MPNs) include three major subgroups—polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)—which are characterized by aberrant hematopoietic proliferation with an increased risk of leukemic transformation. Besides the driver mutations, which are JAK2, CALR, and MPL, more than twenty additional mutations have been identified through the use of next-generation sequencing (NGS), which can be involved with pathways that regulate epigenetic modifications, RNA splicing, or DNA repair. The aim of this short review is to highlight the impact of molecular biology on the diagnosis, prognosis, and therapeutic management of patients with PV, ET, and PMF.
format Online
Article
Text
id pubmed-9818322
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98183222023-01-07 Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm Abbou, Norman Piazzola, Pauline Gabert, Jean Ernest, Vincent Arcani, Robin Couderc, Anne-Laure Tichadou, Antoine Roche, Pauline Farnault, Laure Colle, Julien Ouafik, L’houcine Morange, Pierre Costello, Régis Venton, Geoffroy Cells Review BCR::ABL1-negative myeloproliferative neoplasms (MPNs) include three major subgroups—polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)—which are characterized by aberrant hematopoietic proliferation with an increased risk of leukemic transformation. Besides the driver mutations, which are JAK2, CALR, and MPL, more than twenty additional mutations have been identified through the use of next-generation sequencing (NGS), which can be involved with pathways that regulate epigenetic modifications, RNA splicing, or DNA repair. The aim of this short review is to highlight the impact of molecular biology on the diagnosis, prognosis, and therapeutic management of patients with PV, ET, and PMF. MDPI 2022-12-27 /pmc/articles/PMC9818322/ /pubmed/36611899 http://dx.doi.org/10.3390/cells12010105 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Abbou, Norman
Piazzola, Pauline
Gabert, Jean
Ernest, Vincent
Arcani, Robin
Couderc, Anne-Laure
Tichadou, Antoine
Roche, Pauline
Farnault, Laure
Colle, Julien
Ouafik, L’houcine
Morange, Pierre
Costello, Régis
Venton, Geoffroy
Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm
title Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm
title_full Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm
title_fullStr Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm
title_full_unstemmed Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm
title_short Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm
title_sort impact of molecular biology in diagnosis, prognosis, and therapeutic management of bcr::abl1-negative myeloproliferative neoplasm
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818322/
https://www.ncbi.nlm.nih.gov/pubmed/36611899
http://dx.doi.org/10.3390/cells12010105
work_keys_str_mv AT abbounorman impactofmolecularbiologyindiagnosisprognosisandtherapeuticmanagementofbcrabl1negativemyeloproliferativeneoplasm
AT piazzolapauline impactofmolecularbiologyindiagnosisprognosisandtherapeuticmanagementofbcrabl1negativemyeloproliferativeneoplasm
AT gabertjean impactofmolecularbiologyindiagnosisprognosisandtherapeuticmanagementofbcrabl1negativemyeloproliferativeneoplasm
AT ernestvincent impactofmolecularbiologyindiagnosisprognosisandtherapeuticmanagementofbcrabl1negativemyeloproliferativeneoplasm
AT arcanirobin impactofmolecularbiologyindiagnosisprognosisandtherapeuticmanagementofbcrabl1negativemyeloproliferativeneoplasm
AT coudercannelaure impactofmolecularbiologyindiagnosisprognosisandtherapeuticmanagementofbcrabl1negativemyeloproliferativeneoplasm
AT tichadouantoine impactofmolecularbiologyindiagnosisprognosisandtherapeuticmanagementofbcrabl1negativemyeloproliferativeneoplasm
AT rochepauline impactofmolecularbiologyindiagnosisprognosisandtherapeuticmanagementofbcrabl1negativemyeloproliferativeneoplasm
AT farnaultlaure impactofmolecularbiologyindiagnosisprognosisandtherapeuticmanagementofbcrabl1negativemyeloproliferativeneoplasm
AT collejulien impactofmolecularbiologyindiagnosisprognosisandtherapeuticmanagementofbcrabl1negativemyeloproliferativeneoplasm
AT ouafiklhoucine impactofmolecularbiologyindiagnosisprognosisandtherapeuticmanagementofbcrabl1negativemyeloproliferativeneoplasm
AT morangepierre impactofmolecularbiologyindiagnosisprognosisandtherapeuticmanagementofbcrabl1negativemyeloproliferativeneoplasm
AT costelloregis impactofmolecularbiologyindiagnosisprognosisandtherapeuticmanagementofbcrabl1negativemyeloproliferativeneoplasm
AT ventongeoffroy impactofmolecularbiologyindiagnosisprognosisandtherapeuticmanagementofbcrabl1negativemyeloproliferativeneoplasm

Ejemplares similares